BioMarin licenses Fabry disease drug, Teva buys BioXcel neuroscience assets
According to Stocktwits, BioMarin pays $70 million upfront for a Fabry license while Teva buys BioXcel neuroscience assets in bankruptcy court.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Stocktwits, BioMarin this week signed an exclusive worldwide license with South Korea's GC Biopharma and Hanmi Pharm. The deal covers HM15421/GC1134A, a long-acting enzyme replacement therapy for Fabry disease that is still in an early-stage trial. BioMarin is paying $70 million upfront, and the Korean partners can receive up to $405 million in further milestones plus tiered royalties.
Teva also closed its purchase of neuroscience assets from BioXcel Therapeutics through a court-supervised bankruptcy sale. Teva paid $57.5 million upfront and may owe up to $67.5 million in contingent payments.
why it matters
It was a quiet week for biotech dealmaking, with buyers favoring licenses and distressed asset purchases over full company takeovers. The deals are small, so their effect on broad indices is limited, but BMRN and TEVA stand out for their own pipeline strategies.
tags
instruments
sources
- Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking — Stocktwits, 31 October 2026 at 00:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗